OmniAb (OABI) Assets Average (2021 - 2026)
OmniAb (OABI) reported Assets Average of $297.3 million for Q1 2026, down 5.88% year-over-year from $315.9 million in Q1 2025, and down 2.63% on a QoQ basis from $305.3 million in Q4 2025.
OmniAb (OABI) has 6 years of Assets Average data on file, last reported at $297.3 million in Q1 2026.
- Quarterly Assets Average fell 5.88% year-over-year to $297.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $297.3 million (down 5.88% YoY) and the FY2025 annual result came in at $313.2 million, down 10.6% from the prior year.
- Assets Average fell to $297.3 million in Q1 2026 per OABI's latest filing, from $305.3 million in the prior quarter.
- Across five years, Assets Average topped out at $417.1 million in Q1 2023 and bottomed at $236.8 million in Q2 2022.
- The 5-year median for Assets Average is $328.6 million (2024), against an average of $328.0 million.
- The widest annual swing landed in 2022, when Assets Average soared 99.64%; it then slipped 16.08% in 2024.
- Tracing OABI's Assets Average over 5 years: stood at $329.4 million in 2022, then grew by 16.41% to $383.5 million in 2023, then retreated by 14.32% to $328.6 million in 2024, then dropped by 7.08% to $305.3 million in 2025, then retreated by 2.63% to $297.3 million in 2026.
- Per Business Quant, the three latest OABI Assets Average figures stand at $297.3 million (Q1 2026), $305.3 million (Q4 2025), and $302.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | 297.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 297.28 Mn |
| Dec 31, 2025 | 305.30 Mn |
| Sep 30, 2025 | 302.68 Mn |
| Jun 30, 2025 | 300.93 Mn |
| Mar 31, 2025 | 315.87 Mn |
| Dec 31, 2024 | 328.56 Mn |
| Sep 30, 2024 | 334.41 Mn |
| Jun 30, 2024 | 344.91 Mn |
| Mar 31, 2024 | 363.89 Mn |
| Dec 31, 2023 | 383.47 Mn |
| Sep 30, 2023 | 398.47 Mn |
| Jun 30, 2023 | 409.14 Mn |
| Mar 31, 2023 | 417.13 Mn |
| Dec 31, 2022 | 329.41 Mn |
| Sep 30, 2022 | 237.20 Mn |
| Jun 30, 2022 | 236.85 Mn |
| Mar 31, 2022 | 270.68 Mn |
| Dec 31, 2021 | 270.73 Mn |
| Sep 30, 2021 | 118.81 Mn |